Background. Live, multivalent vaccines have historically exhibited interference in humans; live dengue virus (DENV) vaccines have proven no exception.
There is a recognized need for dengue virus (DENV) vaccines [1, 2] , but development has been hampered by unique aspects of dengue epidemiology and biology. The cocirculation of DENV serotypes in endemic regions, and the ability of all 4 DENV serotypes to cause disease in humans [3] , has prompted the World Health Organization to recommend that an effective vaccine should confer immunity to multiple serotypes [4] . A second, perhaps more critical, rationale for tetravalent vaccination arises from the phenomenon of antibodydependent enhancement (ADE), in which preexisting immunity from a DENV infection is thought to facilitate subsequent infection with a heterologous dengue serotype and thereby promote the occurrence of dengue hemorrhagic fever (DHF) [5, 6] . There is concern that a dengue vaccine that would not confer immunity to all 4 DENV serotypes could prime an individual for DHF upon natural exposure to DENV [7] .
Historically, the generation of a balanced immune response with multitypic live viral vaccines has been a challenging task [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The difficulties encountered with the trivalent oral polio vaccine (OPV) may be most analogous to DENV, as OPV contains 3 different serotypes of live polio virus. Seroconversion rates that exceeded 90% for monovalent polio vaccines were reduced to 68% for type 1, 82% for type 2, and 43% for type 3 in trivalent formulations [12] . Decreasing the dose of type 2, which dominated in viremia, seroconversion, and geometric mean titer (GMT), increased seroconversion somewhat to the subdominant serotypes. However, seroconversion to type 3 remained unacceptably low and the imbalance in seroconversion was only overcome with 3 doses of vaccine [13] .
The development of a safe and immunogenic tetravalent live DENV vaccine has proven no less challenging. The 4 liveattenuated vaccine strains developed by Aventis (now Sanofi) Pasteur and Mahidol University elicited high rates of seroconversion and high neutralization titers when administered as mono-, bi-, and trivalent formulations [19] . Notably, none of the bi-and trivalent formulations contained DENV-3, which was later shown to dominate the antibody response in tetravalent formulations [14] . DENV-3 also dominated in causing viremia following tetravalent vaccination, suggesting that DENV-3 had a replicative advantage [15] . As with OPV, multiple doses of the tetravalent vaccine candidate were necessary to achieve seroconversion to 3 or more DENV serotypes. Development of this candidate was terminated after several volunteers developed mild dengue syndromes and DENV-3 viremia following vaccination [16] .
Interference was also observed following the tetravalent administration of the 4 chimeric yellow fever-DENV vaccine viruses, which are live virus vaccines that use an infectious clone of the yellow fever 17D virus strain with the envelope genes of wildtype DENVs inserted [20] . Studies of the tetravalent vaccine candidate in primates demonstrated that decreasing the dose of the dominant serotype (in this case, DENV-4) resulted in increased seroconversion to other serotypes [18] . In a recent trial of the tetravalent candidate in flavivirus-naive human volunteers, the seroconversion rates for some subdominant strains remained ,80% following 2 doses, but increased to 100% for all serotypes with the administration of a third dose [17] .
An earlier version of a third DENV vaccine candidate, the tetravalent live-attenuated DENV vaccine in development by GlaxoSmithKline Biologicals and the Walter Reed Army Institute of Research (WRAIR), is the focus of this analysis. Liveattenuated monovalent candidates for DENV-1-DENV-4 were combined in a factorial trial of 16 different tetravalent vaccine formulations which evaluated all possible permutations of highand low-dose for each serotype [21] . In the present study, we revisit the results of this clinical trial, taking advantage of the factorial design to statistically evaluate whether there is evidence of interactions between serotypes with respect to the neutralizing antibody response to vaccination and the occurrence of adverse events.
METHODS

Data Sources: Monovalent and Tetravalent Clinical Trials
Four DENV serotype strains were attenuated by multiple passages in primary dog kidney (PDK) cells and fetal rhesus lung (FRhL) cells [22] . The candidate strains were evaluated as monovalent vaccine candidates in 54 flavivirus-naive adults (Table 1 ). The methods of this clinical trial have been detailed previously [23] . Monovalent vaccines were administered subcutaneously in doses of 10 6 , 10 6 , 10
5
, and 10 5 plaque-forming units (PFUs) for the 4 DENV serotypes, respectively. The monovalent candidates were later combined into 16 different tetravalent formulations, representing all combinations of high and low dose for each monovalent vaccine strain. The ''high doses'' for DENV-1, DENV-2, DENV-3, and DENV-4 corresponded to the doses for the monovalent formulations. The ''low dose'' was 1.5 log PFUs lower than the high dose for each serotype. The details of this factorial-design clinical trial have been described previously [21] . Fifteen formulations were administered to groups of 3-4 flavivirus-naive adults; 1 formulation (with all 4 serotypes administered at high doses) was administered to 10 individuals. Formulations are denoted by ''L'' or ''H'' for the dose of each serotype in order from DENV-1 through DENV-4 (eg, formulation ''LHHL'' corresponds to low-dose DENV-1, high DENV-2, high DENV-3, low DENV-4). Multiple doses of tetravalent vaccine were administered (3 doses for formulation HHHH and 2 doses for all others) with the majority of individuals receiving a second dose at day 28. This analysis considers only the response to the first dose of vaccine since persistent immune activation has since been shown to interfere with subsequent vaccinations for several months [24] .
Quantification of Immunogenicity-Serological Methods
The neutralizing antibody response to vaccination was assessed by measuring the maximum dilution of sera that yielded a 50% reduction in DENV plaque formation (plaque reduction neutralization titer 50%, PRNT 50 ). The assay was conducted using standard procedures [25] , and the DENV strains used in the PRNT were the parent strains of the vaccine viruses. The PRNT 50 for each of the 4 serotypes were assessed on day 0 (before vaccination) and day 30 (after vaccination) for monovalent candidates or day 28 for tetravalent candidates. For each serotype, an increase in PRNT 50 from ,1:10 before vaccination to $1:10 after vaccination was defined as a seroconversion.
Notably, complement was added to the neutralization mixture when assessing the antibody response to monovalent vaccine; this was omitted when assessing responses to the tetravalent vaccine. Complement has been shown to increase PRNT 50 titers, to a degree that varies by DENV serotype [26] , and it is therefore possible that the antibody titers observed in the monovalent vaccine recipients were higher than would have been observed in the absence of complement. comparisons of GMTs between monovalent and tetravalent vaccine recipients were not performed.
Quantification of Reactogenicity
Adverse reactions to vaccination (fever, chills, nausea, vomiting, abdominal pain, headache, eye pain, myalgia, and arthralgia) were assessed by a symptom diary that volunteers completed daily. Symptom severity was graded as 0 (no disability), 1 (mild-no medication or alteration of daily activity required), 2 (moderate-required medication or changing of activity), or 3 (severe-required bed rest or symptoms not relieved by medication). The occurrence, severity, and duration of adverse reactions to vaccination each day were summarized using the reactogenicity index (RI), a standard metric for assessing vaccine safety at WRAIR that was calculated as follows:
For each day, the maximum severity was selected from the symptoms in each category (eg, for a given day, if a volunteer listed a grade 2 headache and grade 1 eye pain, the value for the category ''Headache or Eye Pain'' for that day would be 2). The severity of adverse events for each category was summed for each day, and the total severity for days 1-21 after vaccination was summed to obtain the RI. The specific symptoms elicited and the duration of reporting differed between formulation HHHH (2 wk) and all others (3 wk), as the clinical trials occurred at different times and with slightly different methodologies. As the RIs for these 2 sets may not be comparable, the RI data for formulation 16 were excluded from analysis.
Statistical Analyses
The effect of changing the dose of a serotype from low to high was evaluated with respect to the vaccine-induced immune response to that serotype and other serotypes. In bivariate analysis, t tests were used to assess whether the GMT of the antibody response to a given serotype differed significantly by whether each of the 4 serotypes was high or low dose. Pearson v-square tests evaluated whether the proportion of individuals seroconverting to each serotype differed significantly by high or low serotype dose.
All multivariate analyses considered the associations of high and low dose for each serotype, controlling for the doses of all serotypes simultaneously, for several outcomes. Four logistic regression models considered the associations between serotype doses and the outcomes of seroconversion to each DENV serotype. Four linear regression models considered the outcomes of serotype-specific log antibody titers. A logistic regression model considered the associations between serotype doses and seroconversion to $3 vs ,3 serotypes. Finally, a linear regression model considered the associations between serotype doses and the RI. For all multivariate models, all possible 2-way interaction terms were entered and then removed by backward elimination using the Wald test.
For all analyses, statistical significance was defined as a P value ,.05. Analyses were conducted using SAS software, version 9.2 (SAS Institute, Cary, NC) and SPSS software for Windows, version 15.0 (SPSS Inc, Chicago, IL).
Human Subjects Clearance
Clinical protocols were reviewed and approved by the institutional review boards of the University of Maryland at Baltimore, the University of Maryland at College Park, and the Human Use Review and Regulatory Agency of the Office of the Army Surgeon General.
RESULTS
Descriptive Results
Following tetravalent vaccination, the mean (6SD) number of serotypes an individual had detectable neutralizing antibodies against at day 28 ranged from 0.33 6 0.57 for formulation LHLL to 2.5 6 1.29 for HLHH (top, Figure 1 ). The wide error bars are an indication of the low numbers of individuals that received each of the 16 formulations. As illustrated in the figure, there was a trend that high doses of DENV-1 were associated with high overall seroconversion rates to DENV serotypes; low doses of DENV-1 were associated with lower seroconversion rates (r S 5 .37, P , .01 by Spearman's rho). The highest reactogenicity index was observed with formulation HLLL (RI 5 33.25, 6 18.10 SD) (bottom, Figure 1 ). The lowest reactogenicity index was observed with HHHL (RI 5 2.33, 6 3.23 SD). As illustrated in the figure, a high dose of DENV-1 tended to be associated with higher reactogenicity, though this was not significant (r S 5 .23, P 5 .06 by Spearman's rho). A positive correlation was observed between the number of seroconversions per subject at day 28 and reactogenicity (r S 5 .53, P , .01).
Comparison of Monovalent and Tetravalent Formulations
There was no difference in seroconversion to DENV-1 between individuals receiving a monovalent DENV-1 formulation (corresponding to high dose) and individuals that receiving high-dose DENV-1 in tetravalent formulations (Figure 2 A) . The monovalent DENV-2 formulation resulted in higher seroconversion to DENV-2 compared with high-dose DENV-2 tetravalent formulations (100% vs 41.2%, P , .01 by Pearson v 2 ). Seroconversion to DENV-3 was low for both the monovalent and high-dose tetravalent formulations, and did not differ between the 2 groups. Seroconversion to DENV-4 was higher following monovalent as compared with high-dose tetravalent vaccination (71.4% vs 22.2%, P 5 .02). Among monovalent formulations, the GMT for DENV-1 was the highest (GMT 5 787), and DENV-2 and DENV-4 were the lowest (GMT 5 42 and GMT 5 80, respectively) (Figure 2 B ). Figure 3A ). High dose DENV-1 also resulted in a higher probability of seroconversion to DENV-3 (44.4% vs 17.9% for high vs low dose DENV-1, P 5 .03) and DENV-4 (25.0% vs 3.6% for high vs low dose DENV-1, P 5 .03). No significant effect of DENV-2 dose was observed for seroconversion to DENV-2 ( Figure 3B ). However, high doses of DENV-2 were associated with lower seroconversion to DENV-1 (41.2% vs 76.7% for high-vs low-dose DENV-2, P 5 .01). High doses of DENV-3 were associated with an increased probability of seroconversion to DENV-4 (24.3% vs 3.7% for high vs low-dose DENV-3, P 5 .03); no effect was observed on seroconversion to DENV-3 ( Figure 3C ). The dose of DENV-4 had no significant effect on seroconversion to any serotype ( Figure 3D ). Four multivariate logistic regression models were constructed, each evaluating the outcome of seroconversion to one DENV serotype while controlling for the doses of all serotypes simultaneously (Table 2) . High doses of DENV-1 resulted in increased Four linear regression models were constructed for serotypespecific log antibody titers following vaccination, conditional on seroconversion to that serotype, and controlling for all serotype doses simultaneously (data not shown). Given that an individual seroconverted to DENV-1 following vaccination, a high dose of DENV-2 was associated with a lower antibody titer to DENV-1 (b 5 21.14, P 5 .01). Given seroconversion to DENV-2, serotype doses did not significantly change the antibody titer to DENV-2. Given seroconversion to DENV-3, a high dose of DENV-4 was associated with a higher antibody titer to DENV-3 (b 5 .78, P 5 .019). Last, given seroconversion to DENV-4, serotype dose did not significantly change the antibody titer to DENV-4.
Effects of Dose on Multitypic Immunogenicity
As a primary concern in implementing tetravalent DENV vaccines is maximizing seroconversion to multiple serotypes, a logistic regression model was constructed to evaluate the association of serotype dose with seroconversion to 0-2 vs 3-4 DENV serotypes, controlling for all serotype doses simultaneously (Table 3) . High-dose DENV-1 was associated with an increased odds of seroconversion to 3-4 serotypes, as compared with low-dose DENV-1 (odds ratio [OR] 5 6.37, P 5 .04). High-dose DENV-2 was borderline associated with decreased seroconversion to 3-4 DENV serotypes (OR 5 .22, P 5 .05). The doses of DENV-3 and DENV-4 were not associated with overall immunogenicity. 
Effect of Dose on Vaccine Reactogenicity
A multivariate linear regression model was constructed to evaluate the effect of serotype dose on the reactogenicity associated with the first dose of tetravalent vaccine (Table 4) . A high dose of DENV-1 was associated with an increased reactogenicity index (OR 5 23.6, P , .01). However, including high-doses of DENV-2, DENV-3, or DENV-4 in formulations containing high-dose DENV-1 resulted in a significant dampening of the association between DENV-1 and increased reactogenicity.
DISCUSSION
The generation of strong antibody responses to all 4 DENV serotypes in tetravalent live DENV vaccines has been problematic due to immunological and/or viral interference between strains. In this study, we characterized interactions between DENV serotypes using data from a factorial-design clinical trial of a tetravalent live-attenuated DENV vaccine candidate that evaluated all combinations of high and low dose for each serotype. Multivariate logistic and linear regression models were used to evaluate the effects of the dose of each serotype on serotype-specific seroconversion, overall immunogenicity, and reactogenicity. We found evidence of both interference and facilitation between DENV serotypes with respect to the immune response to tetravalent vaccination and the occurrence and severity of adverse events.
The shift from monovalent to tetravalent vaccination affected seroconversion rates differently among the DENV serotypes. The serotype demonstrating the strongest immunogenicity in monovalent formulations (DENV-1) did not suffer notable decreases in immunogenicity after incorporation into tetravalent vaccines. In contrast, DENV-2 and DENV-4 demonstrated weaker immunogenicity as monovalent formulations (as evidenced by lower GMTs), and the immunogenicity of each was further decreased in tetravalent formulations. Evaluations of other tetravalent live DENV vaccines have similarly reported that the serotype eliciting the strongest immune response with monovalent administration tends to dominate in tetravalent formulations and that weaker monovalent strains tend to suffer from the greatest interference [18, 19, 27] .
We found evidence of interference as well as facilitation in the overall immune response to tetravalent vaccination. DENV-1 and DENV-2 appeared to antagonize each other, with high doses of one decreasing seroconversion to the other. This was surprising because DENV-2 appeared to be a relatively weak immunogen in both monovalent and tetravalent formulations. In contrast, increasing the dose of the dominant serotype (DENV-1) appeared to facilitate seroconversion to DENV-3 and DENV-4. It is unclear if this is a reflection of increased cross-reactivity or if a specific response to the subdominant components was elicited. Increased seroconversion due to cross-reactivity would seem more probable, since increasing the dose of DENV-1 would likely increase its competitive advantage, further suppressing the replication of other serotypes. However, facilitated induction of immunity to less immunogenic types cannot be excluded.
It is a well-known limitation of current serological assays that cross-reactive and serotype-specific antibodies cannot be discerned, complicating the interpretation of immunogenicity data from multivalent DENV vaccine trials. Nonetheless, while there is evidence of an association between crossreactive antibodies and DHF [6] , there is also evidence that higher titers of cross-reactive antibodies can be associated with protection from illness [6, [28] [29] [30] . Therefore, whether cross-reactive or specific, one may define a favorable immune response to tetravalent vaccination as one that is both broad (directed against all 4 serotypes) and high-titer. The finding that high doses of the dominant serotype (DENV-1) increased overall seroconversion rates suggests that facilitation between serotypes, once identified, could be exploited to enhance the overall immunogenicity of tetravalent vaccines. Field efficacy studies of tetravalent vaccine candidates are needed to provide insight into the degree of protection afforded against each serotype. These analyses suggest that the total dose of virus administered in a multivalent vaccine and reactogenicity are not necessarily correlated, since increasing the dose of non-DENV-1 serotypes decreased the overall reactogenicity of the formulations. This suggests that increasing the dose of subdominant strains may paradoxically serve to dampen the overall reactogenicity associated with tetravalent formulations, perhaps due to an improved competitive advantage of the subdominant strains. These findings may inform future efforts to optimize vaccine doses for multivalent vaccines by suggesting a means to increase overall seroconversion rates without associated increases in the occurrence of vaccine-associated adverse events.
This analysis was subject to limitations. The numbers of subjects receiving each vaccine formulation were small, and it was not possible to assess higher-order statistical interactions between serotypes. The monovalent and tetravalent clinical trials were conducted at different centers and at different points in time, and it is possible that results are not strictly comparable. A second dose of tetravalent vaccine for most subjects was administered 1 month after the first; it has since been concluded that cross-reactivity and persistent immune activation following an initial dose of vaccine interferes with subsequent doses for up to 6 months [18, 24] . Subsequently, the immunogenicity data following the second dose for this clinical trial were not informative. The generalizability of this study is limited by the fact that interserotypic interactions will depend upon passage histories, strains used, and the nature of the vaccine (eg, liveattenuated or chimeric), and the patterns of serotype-specific interactions observed may not be translatable to other vaccine candidates [31] . Finally, it is important to note that while antibody titers were used widely in this analysis as simple quantitative indicators of serotype interactions, antibody-mediated immunity (particularly in flavivirus-naive individuals) is unlikely to be a primary mechanism involved in these effects. Rather, competition following multivalent vaccination is more likely to be mediated by some earlier-acting combination of viral interference and immunological interference mediated by the innate immune response; at present, these mechanisms are not well understood and not easily measured.
In addition to dose adjustments, other methods of overcoming interference in DENV vaccines have been demonstrated. It is unlikely that any tetravalent live DENV vaccine will be able to confer broad immunity following a single dose to naive subjects; thus, a multiple-dose immunization schedule will likely be necessary. Studies have demonstrated the importance of allowing sufficient time to elapse between doses to minimize the effects of persistent immune activation [22, 30] . Multisite vaccination has been suggested to decrease interference by allowing DENV serotypes to replicate in different sites of the body [18, 32] . Finally, previous studies have shown that the antibody response to tetravalent vaccination is stronger and broader in the setting of preexisting DENV, Japanese encephalitis virus, or yellow fever virus immunity [33, 34] . It may be that interference may be a less important issue in populations with prevalent immunologic priming against DENV and non-DENV flaviviruses.
The unique clinical trial design allowed an unprecedented opportunity to look at how changes in the dose of one serotype influenced the serological response to another. Other tetravalent candidates have evaluated only a small number of formulations with select dosing changes [15, 21] , but none have evaluated the influence of serotype dose using a full factorial design. In this study, we present evidence of interference as well as facilitation between serotypes in the tetravalent live dengue candidate evaluated. These analyses suggest that it may be possible to exploit facilitation to increase overall seroconversion and that increasing the dose of subdominant serotypes may decrease reactogenicity. 
